



Contact: Mitchell Sanders, Ph.D.
Location: Worcester MA 01605
Email: Sanders@ecibiotech.com
Tel: 508 752-2209
Website: www.ecibiotech.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Biotechnology

Company Overview: ECI Biotech, Inc. (ECI) is a premier developer and manufacturer of innovative, patented **ExpressDetect® Diagnostics** products for rapid infection determination at the point-of-care (PoC) to be used by the healthcare providers as well as consumer OTC markets.

Target Market(s): Bioburden **Detection for Advanced WoUnd care**
Approximately 65 mm wounds are treated worldwide annually, of which 14 mm are chronic wounds

Other Markets:

Yeast Infection (80mm worldwide)
Urinary Tract Infection (8.3 mm office visits annually)

Key Value Drivers

Technology*: **ExpressDetect®** simple inexpensive rapid and safe diagnostics

Competitive Advantage: 18 Patents issuing WORLD-WIDE, Fortune 100 Partners

Plan & Strategy:

ExpressDetect® Point of Care Wound Bioburden Sensor:

SBIR Phase I funding secured (\$200k)
Diagnostic target selected and threshold of the chemistry set
Clinical studies indicate excellent sensitivity and specificity profiles
Phase II SBIR Funding secured (\$949k)
Pre-IDE (Investigational Device Exemption) meeting in preparation
Suppliers and Partners identified
Selected for NIH CAP-ACT Program

Management

Leadership: Mitchell Sanders, Ph.D.
Chief Executive Officer and Founder

Geert Cauwenbergh, Ph.D., Chair of the Advisory Board

Tara Sharif, Ph.D., MBA
V.P., Business Development

Board of Directors:

Mike Landine, Alkermes
Walter Winshall, Collaborative Seed and Growth Partners
Dana Edelman, Collaborative Seed and Growth Partners
Benoit Jamar, Vik Brothers International
Gustav Vik, Vik Brothers International
Geert Cauwenbergh, Phase I23
Mitchell Sanders ECI Biotech

Product Pipeline

ExpressDetect® Consumer Strep Diagnostic:

Diagnostic targets identified and the threshold of the chemistry set
Development Partner secured

ExpressDetect® Yeast Diagnostic:

Diagnostic targets identified and the threshold of the chemistry set
Phase I Grant Funded (\$200k)
Clinical studies underway
Pre-IDE meeting in preparation
Suppliers and Partners identified